ClinicalTrials.gg
CompletedNCT01183143PrestyjeUpdated Apr 6, 2018Results posted

Convenience and Safety of Assisted Reproductive Technology Procedures Using a Gonal-F Filled by Mass (Fbm) Liquid Formulation Applied by Pen for Ovulation Induction and In-vitro Fertilization

A Phase 3 interventional study of GONAL-f® in Infertility, Ovulation Induction and In-Vitro Fertilization, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to female participants aged 18 Years to 43 Years. Per ClinicalTrials.gov, last updated 2018-04-06.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 6 years 3 months after the study started (first participant enrolled May 2004, registered Aug 2010).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
215
Allocation
Not applicable
Ages
18 Years to 43 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing follitropin alfa in Infertility — 3 open to participants now, 4 under way, 1 of them phase 3. follitropin alfa · Infertility.

Enrollment
11th of 30
215 · median 159
Started
2004
with 1 other
Phase 3
9 of 30
1 open now
Registered
11th of 30
by date
Lead sponsor
8 of 30
Merck KGaA, Darmstadt, Germany

Among the 30 studies testing follitropin alfa in Infertility, this one is the 11th largest by enrollment, is one of 2 that started in 2004, is one of 9 in phase 3, and was the 11th registered.

Infertility

2,088 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

3 of the 30 studies testing follitropin alfa in Infertility are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About follitropin alfa

follitropin alfa: first FDA approval 1997 (Gonal-f), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 43 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing follitropin alfa in Infertility, or all of them as a file.
02

Study summary

This was a prospective, open-label, non-comparative, Phase IIIb trial to assess the convenience, safety and efficacy of the new Gonal-F fbm [recombinant follicle stimulating hormone (r-FSH)] liquid formulation, in common setting for ovulation induction (OI) and also in in-vitro fertilization (IVF).

03

Conditions studied

  • Infertility
  • Ovulation Induction
  • In-Vitro Fertilization

Browse trials for

Keywords

  • Infertility
  • Ovulation induction
  • Gonal-F
  • Follitropin alpha
  • Controlled ovarian stimulation
04

Who can participate

Ages eligible
18 Years to 43 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subjects aged between 18 and 43 years
  • Ambulatory subjects
  • Subjects who are willing to get pregnant and are infertile, that justifies ovarian stimulation treatment for mono-/pauci-follicular development (OI or IUI) or multiple follicular development for IVF/Intracytoplasmic Sperm Injection (ICSI) procedures
  • Subjects who are able to communicate well with the investigator and to comply with the requirements of the entire study
  • Subjects who have given written , prior to treatment

Exclusion criteria

Exclusion Criteria:

  • Subjects with enlarged ovaries or cysts unrelated to polycystic ovaries
  • Subjects with extra-uterine pregnancy during the last 3 months
  • Subjects with several endometriosis (Grade III \& IV)
  • Subjects with history of severe ovarian hyperstimulation syndrome
  • Subjects with history of thromboembolic event
  • Subjects with malformative uterine pathology that could disturb either implantation or pregnancy processes
  • Subjects with premature menopause
  • Subjects with gynecological bleeding of unknown origin
  • Subjects with ovarian, uterine, or mammary cancer
  • Subjects with tumors of the hypothalamus or the pituitary glands
  • Subjects with history of serious allergy or atopic asthma disease
  • Subjects with known allergic reaction against one of the Follicle Stimulating Hormone (FSH) and ingredients,
  • Ongoing pregnant, or breast feeding subjects
  • Subjects who have participated in a trial during the last 3 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
215 participants (actual)

Study arms

  • Experimental
    GONAL-f®

    Drug: GONAL-f®

Interventions

  • GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro fertilization (IVF). For subjects who undergo OI/IUI, the dose will be increased by 37.5 IU after Day 14 up to Week 4 if no ovarian response is observed.

    Also known as: Follitropin alpha

06

What researchers measure

Primary outcomes

  1. Number of Subjects Who Self-administered the Investigational Medicinal Product (IMP)

    Number of subjects who self-administered the IMP were presented in this outcome measure.

    Time frame: Up to 1 year

Secondary outcomes

  1. Global Evaluation of the GONAL-f® Prefilled Pen by the Investigator

    Investigator evaluated the use of GONAL-f® prefilled pen in subjects as very satisfactory, satisfactory and average satisfaction.

    Time frame: Up to 1 year

  2. Evaluation of the Information Given to the Subjects on the Pen's Utilization

    Subjects were provided with the information on Pen's utilization via training session and in the form of information brochure. Subjects assessed both the methods using the following responses: satisfactory, satisfactory, unsatisfactory and very unsatisfactory.

    Time frame: Up to 1 year

  3. Duration of Ovarian Stimulation With GONAL-f®

    Stimulation duration was defined as the duration (in days) for which subjects underwent GONAL-f® treatment.

    Time frame: Up to 1 year

  4. Mean Number of Embryos Transferred

    Time frame: End of Stimulation period (up to a maximum 26 days)

  5. Total and Average Daily Dose of GONAL-f®

    Time frame: Up to 26 days

  6. Pregnancy Rate in Subjects Receiving Stimulation by Ovulation Induction (OI) or Artificial Insemination (IUI)

    Pregnancy rate was defined as the percentage of subjects with diagnosis of pregnancy, who underwent OI/IUI. Clinical pregnancy: Evidence of pregnancy by clinical or ultrasound parameters at 12 weeks after fertilization. Biochemical pregnancy: Evidence of conception based only on biochemical data in the serum or urine before ultrasound evidence of a gestational sac. Ongoing pregnancy was defined when the pregnancy had completed 20 weeks of gestation.

    Time frame: Up to 20 Weeks of Gestation

  7. Number of Subjects With Live Birth

    Number of subjects whose stimulation with the IMP resulted in the birth of a baby were reported.

    Time frame: End of Gestation period, assessed up to a maximum of 1 year

  8. Number of Subjects With Local Tolerance at GONAL-f ® Injection Site as Assessed by Investigator

    Local tolerance at the GONAL-f ® injection site was assessed for the presence of pain, swelling/welt, redness, itch and haematoma.

    Time frame: Up to 1 year

  9. Number of Subjects With at Least 1 Adverse Event

    An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerged or worsened relative to baseline (i.e. present at the initial study visit) during a clinical study with an investigational product, regardless of causal relationship and even if no investigational product has been administered.

    Time frame: Up to 1 year

  10. Number of Subjects Taking at Least 1 Concomitant Treatment

    Time frame: Up to 1 year

07

Results

Posted Apr 6, 2018

Participant flow

Participant flow — Overall Study
MilestoneGONAL-f®
Started215
Intention to treat (itt) population204
Completed65
Not completed150
Withdrew: Protocol violation115
Withdrew: Withdrawal by subject19
Withdrew: Subject questionnaires not returned5
Withdrew: Subjects enrolled, but not treated11

Outcome measures

PrimaryNumber of Subjects Who Self-administered the Investigational Medicinal Product (IMP)

Number of subjects who self-administered the IMP were presented in this outcome measure.

Time frame:
Up to 1 year
Reported as:
Number · subjects
Number of Subjects Who Self-administered the Investigational Medicinal Product (IMP)
subjectsGONAL-f®
Number of Subjects Who Self-administered the Investigational Medicinal Product (IMP)159
SecondaryGlobal Evaluation of the GONAL-f® Prefilled Pen by the Investigator

Investigator evaluated the use of GONAL-f® prefilled pen in subjects as very satisfactory, satisfactory and average satisfaction.

Time frame:
Up to 1 year
Reported as:
Number · subjects
Global Evaluation of the GONAL-f® Prefilled Pen by the Investigator
subjectsGONAL-f®
Very satisfactory101
Satisfactory93
Average satisfaction1
SecondaryEvaluation of the Information Given to the Subjects on the Pen's Utilization

Subjects were provided with the information on Pen's utilization via training session and in the form of information brochure. Subjects assessed both the methods using the following responses: satisfactory, satisfactory, unsatisfactory and very unsatisfactory.

Time frame:
Up to 1 year
Reported as:
Number · subjects
Evaluation of the Information Given to the Subjects on the Pen's Utilization
subjectsGONAL-f®
Training Session: Very satisfactory89
Training Session: Satisfactory95
Training Session: Unsatisfactory5
Training Session: Very unsatisfactory1
Information brochure: Very satisfactory95
Information brochure: Satisfactory89
Information brochure: Unsatisfactory9
Information brochure: Very unsatisfactory2
SecondaryDuration of Ovarian Stimulation With GONAL-f®

Stimulation duration was defined as the duration (in days) for which subjects underwent GONAL-f® treatment.

Time frame:
Up to 1 year
Reported as:
Median · days
Duration of Ovarian Stimulation With GONAL-f®
daysGONAL-f®
Duration of Ovarian Stimulation With GONAL-f®10 (3 to 26)
SecondaryMean Number of Embryos Transferred
Time frame:
End of Stimulation period (up to a maximum 26 days)
Reported as:
Mean · embryos
Mean Number of Embryos Transferred
embryosGONAL-f®
Mean Number of Embryos Transferred1.8 ± 0.7
SecondaryTotal and Average Daily Dose of GONAL-f®
Time frame:
Up to 26 days
Reported as:
Mean · International Units (IU)
Total and Average Daily Dose of GONAL-f®
International Units (IU)GONAL-f®
Total dose1527 ± 964
Daily dose149.5 ± 75.9
SecondaryPregnancy Rate in Subjects Receiving Stimulation by Ovulation Induction (OI) or Artificial Insemination (IUI)

Pregnancy rate was defined as the percentage of subjects with diagnosis of pregnancy, who underwent OI/IUI. Clinical pregnancy: Evidence of pregnancy by clinical or ultrasound parameters at 12 weeks after fertilization. Biochemical pregnancy: Evidence of conception based only on biochemical data in the serum or urine before ultrasound evidence of a gestational sac. Ongoing pregnancy was defined when the pregnancy had completed 20 weeks of gestation.

Time frame:
Up to 20 Weeks of Gestation
Reported as:
Number · Percentage of subjects
Pregnancy Rate in Subjects Receiving Stimulation by Ovulation Induction (OI) or Artificial Insemination (IUI)
Percentage of subjectsGONAL-f®
Clinical pregnancy16.5 (8.6 to 24.4)
Biochemical pregnancy16.5 (8.6 to 24.4)
Ongoing pregnancy16.5 (8.6 to 24.4)
SecondaryNumber of Subjects With Live Birth

Number of subjects whose stimulation with the IMP resulted in the birth of a baby were reported.

Time frame:
End of Gestation period, assessed up to a maximum of 1 year
Reported as:
Number · subjects
Number of Subjects With Live Birth
subjectsGONAL-f®
Number of Subjects With Live Birth41
SecondaryNumber of Subjects With Local Tolerance at GONAL-f ® Injection Site as Assessed by Investigator

Local tolerance at the GONAL-f ® injection site was assessed for the presence of pain, swelling/welt, redness, itch and haematoma.

Time frame:
Up to 1 year
Reported as:
Number · subjects
Number of Subjects With Local Tolerance at GONAL-f ® Injection Site as Assessed by Investigator
subjectsGONAL-f®
Pain32
Swelling/welt3
Redness34
Itch8
Haematoma41
SecondaryNumber of Subjects With at Least 1 Adverse Event

An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerged or worsened relative to baseline (i.e. present at the initial study visit) during a clinical study with an investigational product, regardless of causal relationship and even if no investigational product has been administered.

Time frame:
Up to 1 year
Reported as:
Number · subjects
Number of Subjects With at Least 1 Adverse Event
subjectsGONAL-f®
Number of Subjects With at Least 1 Adverse Event36
SecondaryNumber of Subjects Taking at Least 1 Concomitant Treatment
Time frame:
Up to 1 year
Reported as:
Number · subjects
Number of Subjects Taking at Least 1 Concomitant Treatment
subjectsGONAL-f®
Number of Subjects Taking at Least 1 Concomitant Treatment28

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GONAL-f®—6/215 (2.8%)36/215 (16.7%)
Most frequent serious events
Most frequent serious events
EventGONAL-f®
Ectopic pregnancyPregnancy, puerperium and perinatal conditions2/215
Abortion spontaneous NOSPregnancy, puerperium and perinatal conditions1/215
Placental, amniotic and cavity disordersPregnancy, puerperium and perinatal conditions1/215
Uterine contractions during pregnancyPregnancy, puerperium and perinatal conditions1/215
Ovarian hyperstimulation syndromeReproductive system and breast disorders1/215
Uterine dilation and curettageSurgical and medical procedures1/215
Most frequent other events
Showing 10 of 16
Most frequent other events
EventGONAL-f®
Injection site haemorrhageGeneral disorders15/215
Injection site erythemaGeneral disorders4/215
Injection site painGeneral disorders4/215
Ovarian hyperstimulation syndromeReproductive system and breast disorders4/215
Abortion spontaneous NOSPregnancy, puerperium and perinatal conditions3/215
Injection site pruritusGeneral disorders2/215
Abdominal pain upperGastrointestinal disorders1/215
NauseaGastrointestinal disorders1/215
AstheniaGeneral disorders1/215
Pelvic infectionInfections and infestations1/215

Baseline characteristics

The ITT population included all the subjects who received at least 1 dose of the IMP.

Age, Continuous
Age, Continuous(years)GONAL-f®
Mean30.0 ± 3.3
Sex: Female, Male
Sex: Female, Male(Participants)GONAL-f®
Female204
Male0
08

Study locations

1 site
  • Please Contact the Merck KGaA Communication Center
    Darmstadt, 64293, Germany
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2004 to primary completion in Mar 2006, 21 months.

Results were first posted in Apr 2018, 12 years 1 month after primary completion.

Of 25 industry-sponsored phase 3 interventional studies under Infertility, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 21 months is above that.

Counting every sponsor, half of 59 studies reached it within 24 months; a quarter within 16 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 16, 2010
First posted
Aug 17, 2010
StartActual
May 11, 2004
Primary completionActual
Mar 2, 2006
CompletionActual
Mar 2, 2006
Results first posted
Apr 6, 2018
Last update
Apr 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01183143
Responsible party
Sponsor
First posted
Aug 17, 2010
Start date
May 11, 2004
Primary completion
Mar 2, 2006
Completion
Mar 2, 2006
Results posted
Apr 6, 2018
Last update
Apr 6, 2018

Study contacts

Medical Responsible
study director · Merck KGaA, Darmstadt, Germany
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin alfa

Start the discussion